Search Videos and More
Video
ARC-20 Study Presented by Toni Choueiri, MD.
Toni Choueiri, MD, of Dana-Farber Cancer Institute presents first results from the ARC-20 trial evaluating casdatifan (HIF-2 inhibitor) + cabozantinib (VEGF TKI) in metastatic clear cell kidney cancer.
Video
Talazoparib + Tazemetostat Presented by Atish Choudhury, MD, PhD.
Dr. Atish Choudhury presented clinical trial results evaluating the combination of talazoparib and tazemetostat in advanced prostate cancer.
Video
Phase 2 PROSPECT Study Presented by Lakshmi Nayak, MD.
Lakshmi Nayak, MD presented results from a phase 2 PROSPECT study focused on tirabrutinib and it's effect on patients with relapsed or refractory primary central nervous system lymphoma.
Video
TRADE Study Presented by Erica Mayer, MD.
Dr. Erica Mayer shares results from the TRADE study showing a successful abemaciclib dose escalation strategy in patients with HR+ breast cancer.
Video
ReACT 1.0 Study Presented by Glenn Hanna, MD.
Dr. Glenn Hanna presented phase 2 data suggesting that circulating HPV DNA could serve as a real-time biomarker to guide treatment intensity in HPV-positive oropharyngeal cancer.
Video
Stereotactic Radiation Presented by Ayal Aizer, MD.
Dr. Ayal Aizer of Dana-Farber Brigham Cancer Center presents results at #ASCO25 from a phase 3 trial on stereotactic radiation.
Video
DESTINY-Breast09 Presented by Sara Tolaney, MD, MPH.
Dr. Sara Tolaney of Dana-Farber shares pivotal results from the DESTINY-Breast09 phase 3 trial.
Video
Checkmate 214 Presented by Toni Choueiri, MD.
Dr. Toni Choueiri shares groundbreaking 9-year results from the CHECKMATE-214 trial.
Document
Treatment Guideline: Datopotamab Deruxtecan (Dato-DXd) in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer
Our Breast Oncology Center held multidisciplinary meetings to discuss recommendations regarding the use of datopotamab deruxtecan (Dato-DXd) in patients with hormone receptor-positive/HER2-negative metastatic breast cancer.
News
T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer
In an interim analysis from the DESTINY-Breast09 study, the combination of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) plus pertuzumab, nearly doubled progression-free survival compared to the currently accepted standard treatment with taxane chemotherapy plus trastuzumab and pertuzumab (THP) for first-line therapy of metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
News
Dana-Farber Research News 06.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 1 through May 15.
News
Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds
A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.